MINNEAPOLIS--(BUSINESS WIRE)--Urologix®, Inc. (NASDAQ:ULGX), a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ treatment catheters that provide a durable and effective procedure delivered in the comfort of an urologist’s office for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the fiscal 2010 second quarter ended December 31, 2009.
